Edition:
United Kingdom

Orexigen Therapeutics Inc (OREX.OQ)

OREX.OQ on NASDAQ Stock Exchange Global Select Market

1.18USD
7:38pm GMT
Change (% chg)

$0.20 (+20.41%)
Prev Close
$0.98
Open
$1.00
Day's High
$1.19
Day's Low
$1.00
Volume
201,082
Avg. Vol
44,660
52-wk High
$4.66
52-wk Low
$0.80

Select another date:

Fri, Jan 19 2018

BRIEF-Orexigen Therapeutics Says ‍Expect Annualized Savings Associated With Feb 2018 Reduction In Sales Force Of About $30 Mln​

* OREXIGEN THERAPEUTICS SAYS ‍EXPECT ANNUALIZED SAVINGS ASSOCIATED WITH FEB 2018 REDUCTION IN SALES FORCE OF ABOUT $30 MILLION​ - SEC FILING Source text: (http://bit.ly/2Bg6XUc) Further company coverage:

BRIEF-Man Group Plc Reports 8.54 Pct Passive Stake In Orexigen Therapeutics

* MAN GROUP PLC REPORTS 8.54 PERCENT PASSIVE STAKE IN OREXIGEN THERAPEUTICS INC AS OF NOVEMBER 27 - SEC FILING‍​ Source text : http://bit.ly/2AKRpMo Further company coverage:

BRIEF-Orexigen Says Entered Into Exchange Agreements With Holders

* OREXIGEN - ENTERED INTO EXCHANGE AGREEMENTS WITH HOLDERS OF 2.75% CONVERTIBLE EXCHANGE SENIOR NOTES DUE 2020, 2.75% CONVERTIBLE SENIOR NOTES DUE 2020

BRIEF-Orexigen Therapeutics Q3 loss per share $1.35

* Orexigen Therapeutics announces third quarter 2017 financial results

BRIEF-Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt

* Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt, Germany for contrave in Latin America

BRIEF-Orexigen Therapeutics - pursuing potential actions including merger or sale of co

* Orexigen Therapeutics Inc says ‍expects total revenues for Q3 of 2017 to be between about $18.1 million and $19.1 million-SEC filing​

BRIEF-Orexigen announces favorable decision from U.S. court in patent litigation, confirming exclusivity for Contrave through 2030

* Orexigen announces favorable decision from U.S. District Court in patent litigation, confirming exclusivity for Contrave through 2030

BRIEF-Orexigen Therapeutics sees 2017 net sales $85 mln to $100 mln - presentation slides‍​

* Orexigen Therapeutics Inc sees Orexigen net sales $85 million to $100 million for 2017 - presentation slides‍​ Source text: (http://bit.ly/2fpwCRS) Further company coverage:

BRIEF-Orexigen Therapeutics to provide business update

* Orexigen Therapeutics to provide business update at the 2017 Cantor Fitzgerald Global Healthcare Conference Source text for Eikon: Further company coverage:

Select another date: